TY  - JOUR
A1  - Merker, Michael
A1  - Meister, Michael T.
A1  - Heinze, Annekathrin
A1  - Jarisch, Andrea
A1  - Sörensen, Jan
A1  - Hünecke, Sabine
A1  - Bremm, Melanie
A1  - Cappel, Claudia
A1  - Klingebiel, Thomas
A1  - Bader, Peter
A1  - Rettinger, Eva
T1  - Adoptive cellular immunotherapy for refractory childhood cancers: a single center experience
T2  - Oncotarget
N2  - Prognosis of refractory childhood cancers despite multimodal treatment strategies remains poor. Here, we report a single center experience encountered in 18 patients with refractory solid malignancies treated with adoptive cellular immunotherapy (ACI) from haploidentical or matched donors following hematopoietic stem cell transplantation. While seven patients were in partial and six in complete remission (CR), five patients suffered from relapsed diseases at the time of ACI. 1.5-year probabilities of overall survival (OS) and progression-free survival (PFS) were 19.5% and 16.1% for all patients. Patients in CR showed estimated 1.5-year OS and PFS of 50.1% and 42.7%, respectively. CR was induced or rather sustained in ten children, with two still being alive 9.6 and 9.3 years after ACI. Naïve, central and effector memory T-cells correlated with responses. However, the majority of patients relapsed. Cumulative incidence of relapse was 79.8% at 1.5 years. Acute graft versus host disease (aGVHD) occurred in nine of 18 patients (50%) with aGVHD grade I–II observed in six (33%) and aGVHD grade III seen in three (17%) patients, manageable in all cases.
Altogether, study results indicate that donor-derived ACI at its current state offers palliation but no clear curative benefit for refractory childhood cancers and warrants further improvement.
Y1  - 2019
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/75551
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-755514
SN  - 1949-2553
VL  - 10
IS  - 58
SP  - 6138
EP  - 6151
PB  - Impact Journals LLC
ER  -